Lipum AB (publ) (LIPUM.ST)
SEK 13.3
(-1.48%)
SEK 13.3
(-1.48%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -8.46 Million SEK | 72.85% |
| 2022 | -31.17 Million SEK | 31.46% |
| 2021 | -45.48 Million SEK | -1434.84% |
| 2020 | -2.96 Million SEK | 80.7% |
| 2019 | -15.35 Million SEK | -82.08% |
| 2018 | -8.43 Million SEK | -203.85% |
| 2017 | -2.77 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -1.09 Million SEK | 94.04% |
| 2024 Q2 | -18.37 Million SEK | -6478.47% |
| 2024 Q1 | 288 Thousand SEK | 103.4% |
| 2023 Q2 | -10.7 Million SEK | 57.37% |
| 2023 Q4 | -8.46 Million SEK | 46.73% |
| 2023 FY | -8.46 Million SEK | 72.85% |
| 2023 Q3 | -15.89 Million SEK | -48.46% |
| 2023 Q1 | -25.1 Million SEK | 19.48% |
| 2022 FY | -31.17 Million SEK | 31.46% |
| 2022 Q4 | -31.17 Million SEK | -293.84% |
| 2022 Q3 | -7.91 Million SEK | 54.02% |
| 2022 Q2 | -17.21 Million SEK | 34.8% |
| 2022 Q1 | -26.4 Million SEK | 41.95% |
| 2021 Q1 | -2.68 Million SEK | 9.27% |
| 2021 FY | -45.48 Million SEK | -1434.84% |
| 2021 Q4 | -45.48 Million SEK | 24.77% |
| 2021 Q3 | -60.46 Million SEK | 10.09% |
| 2021 Q2 | -67.25 Million SEK | -2401.08% |
| 2020 Q3 | -12.8 Million SEK | 0.0% |
| 2020 FY | -2.96 Million SEK | 80.7% |
| 2020 Q4 | -2.96 Million SEK | 76.86% |
| 2019 FY | -15.35 Million SEK | -82.08% |
| 2018 FY | -8.43 Million SEK | -203.85% |
| 2017 FY | -2.77 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 83.077% |
| Ziccum AB (publ) | -2.13 Million SEK | -296.116% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 55.588% |
| BioArctic AB (publ) | -606.58 Million SEK | 98.604% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 83.048% |
| Mendus AB (publ) | -96.29 Million SEK | 91.209% |
| Genovis AB (publ.) | -43.94 Million SEK | 80.736% |
| Intervacc AB (publ) | -88.16 Million SEK | 90.398% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 141.273% |
| Active Biotech AB (publ) | -33.2 Million SEK | 74.503% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 115.905% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 78.505% |
| Aptahem AB (publ) | 2.9 Million SEK | 391.029% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 97.463% |
| Kancera AB (publ) | -45.69 Million SEK | 81.474% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 97.428% |
| Fluicell AB (publ) | -2.76 Million SEK | -206.37% |
| Saniona AB (publ) | 40.44 Million SEK | 120.929% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 73.486% |
| Biovica International AB (publ) | -58.73 Million SEK | 85.588% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 81.279% |
| AcouSort AB (publ) | -23.98 Million SEK | 64.709% |
| Xintela AB (publ) | -7.8 Million SEK | -8.401% |
| Abliva AB (publ) | -57.24 Million SEK | 85.211% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 95.652% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 89.702% |
| OncoZenge AB (publ) | -12.62 Million SEK | 32.961% |
| Amniotics AB (publ) | -5.63 Million SEK | -50.302% |
| 2cureX AB (publ) | -13.4 Million SEK | 36.842% |
| CombiGene AB (publ) | -101.44 Million SEK | 91.655% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -291.717% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 256.759% |
| Camurus AB (publ) | -1.16 Billion SEK | 99.274% |
| Corline Biomedical AB | -17.01 Million SEK | 50.241% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 89.892% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 93.873% |
| I-Tech AB | -83.26 Million SEK | 89.833% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 106.284% |
| Cyxone AB (publ) | -16.67 Million SEK | 49.22% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 84.853% |
| Biosergen AB | -1.88 Million SEK | -349.549% |
| Cantargia AB (publ) | -139.74 Million SEK | 93.943% |
| NextCell Pharma AB | -46.79 Million SEK | 81.909% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 93.463% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 71.191% |
| Nanologica AB (publ) | -9.38 Million SEK | 9.832% |
| SynAct Pharma AB | -61.75 Million SEK | 86.293% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 60.472% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | 36.013% |
| LIDDS AB (publ) | -13.51 Million SEK | 37.352% |
| BioInvent International AB (publ) | -236.3 Million SEK | 96.418% |
| Alzinova AB (publ) | -21.22 Million SEK | 60.12% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 87.351% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -63.388% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 89.891% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -817.118% |
| Simris Alg AB (publ) | 85.07 Million SEK | 109.95% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 89.688% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 105.097% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 59.289% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -184.825% |